CSCs are reported to be the possible culprits behind therapy resistance9, 10 and also responsible for disease recurrence.11 CD133, CD44 and Ep‐CAM have been shown to be specific for CSC cells in CRC and Ep‐CAMhigh/CD44+ positivity has been reported to be associated with metastasis in CRC.12, 13 CD133 has been shown to be an independent prognostic marker for lower survival rate in CRC patients.15 However, there are hardly any studies evaluating CSCs‐associated molecular signatures in surgical margins and their role in CRC prognosis. Here, EPCAM is linked to colorectal carcinoma.